|
GB2324093A
(en)
|
1996-01-04 |
1998-10-14 |
Rican Limited |
Helicobacter pylori bacterioferritin
|
|
WO2000011181A1
(en)
|
1998-08-20 |
2000-03-02 |
Connaught Laboratories Limited |
NUCLEIC ACID MOLECULES ENCODING INCLUSION MEMBRANE PROTEIN C OF $i(CHLAMYDIA)
|
|
EP1105489A1
(en)
|
1998-08-20 |
2001-06-13 |
Aventis Pasteur Limited |
Nucleic acid molecules encoding pomp91a protein of chlamydia
|
|
US6686339B1
(en)
|
1998-08-20 |
2004-02-03 |
Aventis Pasteur Limited |
Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
|
|
US6649370B1
(en)
|
1998-10-28 |
2003-11-18 |
Aventis Pasteur Limited |
Chlamydia antigens and corresponding DNA fragments and uses thereof
|
|
US6607730B1
(en)
|
1998-11-02 |
2003-08-19 |
Aventis Pasteur Limited/Aventis Pasteur Limitee |
Chlamydia antigens and corresponding DNA fragments and uses thereof
|
|
CA2353107A1
(en)
|
1998-12-01 |
2000-06-08 |
Andrew D. Murdin |
Chlamydia antigens and corresponding dna fragments and uses thereof
|
|
US20020061848A1
(en)
|
2000-07-20 |
2002-05-23 |
Ajay Bhatia |
Compounds and methods for treatment and diagnosis of chlamydial infection
|
|
JP2002531129A
(ja)
|
1998-12-08 |
2002-09-24 |
コリクサ コーポレイション |
クラミジア感染の処置および診断のための化合物および方法
|
|
GB9828000D0
(en)
|
1998-12-18 |
1999-02-10 |
Chiron Spa |
Antigens
|
|
US7297341B1
(en)
|
1998-12-23 |
2007-11-20 |
Sanofi Pasteur Limited |
Chlamydia antigens and corresponding DNA fragments and uses thereof
|
|
US6808713B1
(en)
|
1998-12-28 |
2004-10-26 |
Aventis Pasteur Limited |
Chlamydia antigens and corresponding DNA fragments and uses thereof
|
|
JP2002541766A
(ja)
|
1998-12-28 |
2002-12-10 |
アベンティス、パストゥール、リミテッド |
クラミジア抗原および対応するdna断片ならびにその使用
|
|
GB9902555D0
(en)
|
1999-02-05 |
1999-03-24 |
Neutec Pharma Plc |
Medicament
|
|
MXPA01009256A
(es)
|
1999-03-12 |
2003-07-14 |
Aventis Pasteur |
Antigenos de chlamydia y fragmentos de acido desoxirribonucleico correspondientes y usos de los mismos.
|
|
DE60036698T2
(de)
|
1999-05-03 |
2008-07-24 |
Sanofi Pasteur Ltd., Toronto |
Chlamydia-antigene und entsprechende dna-fragmente und deren verwendungen
|
|
NZ517952A
(en)
|
1999-09-20 |
2004-01-30 |
Aventis Pasteur |
Chlamydia antigens and corresponding DNA fragments and uses thereof
|
|
US6632663B1
(en)
|
1999-09-22 |
2003-10-14 |
Aventis Pasteur Limited |
DNA immunization against chlamydia infection
|
|
EP1240331B1
(en)
|
1999-12-22 |
2010-04-07 |
Aventis Pasteur Limited |
Chlamydia antigens and corresponding dna fragments and uses thereof
|
|
WO2001081379A2
(en)
|
2000-04-21 |
2001-11-01 |
Corixa Corporation |
Compounds and methods for treatment and diagnosis of chlamydial infection
|
|
AU2001258105A1
(en)
|
2000-05-08 |
2001-11-20 |
Aventis Pasteur Limited |
Chlamydia antigens and corresponding dna fragments and uses thereof
|
|
JP2004502415A
(ja)
|
2000-07-03 |
2004-01-29 |
カイロン エセ.ピー.アー. |
Chlamydiapneumoniaeに対する免疫化
|
|
CA2881568C
(en)
|
2000-10-27 |
2019-09-24 |
Novartis Vaccines And Diagnostics, Inc. |
Nucleic acids and proteins from streptococcus groups a & b
|
|
GB0107658D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Streptococcus pneumoniae
|
|
GB0107661D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Staphylococcus aureus
|
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
|
GB0118249D0
(en)
|
2001-07-26 |
2001-09-19 |
Chiron Spa |
Histidine vaccines
|
|
GB0121591D0
(en)
|
2001-09-06 |
2001-10-24 |
Chiron Spa |
Hybrid and tandem expression of neisserial proteins
|
|
RU2331435C2
(ru)
|
2001-12-12 |
2008-08-20 |
Чирон Срл. |
Иммунизация против chlamydia trachomatis
|
|
EP2572707A3
(en)
|
2002-02-20 |
2013-11-06 |
Novartis Vaccines and Diagnostics, Inc. |
Microparticles with adsorbed polypeptide-containing molecules
|
|
GB0220194D0
(en)
|
2002-08-30 |
2002-10-09 |
Chiron Spa |
Improved vesicles
|
|
CA2503946C
(en)
|
2002-11-01 |
2016-08-16 |
Glaxosmithkline Biologicals S.A. |
Drying process
|
|
US7807802B2
(en)
|
2002-11-12 |
2010-10-05 |
Abbott Lab |
Polynucleotides for the amplification and detection of Chlamydia trachomatis and Neisseria gonorrhoeae
|
|
EP1562982B1
(en)
|
2002-11-15 |
2010-05-05 |
Novartis Vaccines and Diagnostics S.r.l. |
Unexpected surface proteins in neisseria meningitidis
|
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
|
WO2004087153A2
(en)
|
2003-03-28 |
2004-10-14 |
Chiron Corporation |
Use of organic compounds for immunopotentiation
|
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
|
JP5557415B2
(ja)
|
2003-06-02 |
2014-07-23 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
吸着させたトキソイドおよび多糖類含有抗原を含む微粒子に基づく免疫原性組成物
|
|
WO2006115509A2
(en)
|
2004-06-24 |
2006-11-02 |
Novartis Vaccines And Diagnostics Inc. |
Small molecule immunopotentiators and assays for their detection
|
|
WO2006002422A2
(en)
|
2004-06-24 |
2006-01-05 |
Novartis Vaccines And Diagnostics Inc. |
Compounds for immunopotentiation
|
|
JP2008508320A
(ja)
|
2004-07-29 |
2008-03-21 |
カイロン コーポレイション |
Streptococcusagalactiaeのようなグラム陽性細菌に対する免疫原性組成物
|
|
GB0424092D0
(en)
|
2004-10-29 |
2004-12-01 |
Chiron Srl |
Immunogenic bacterial vesicles with outer membrane proteins
|
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
|
SI1858920T1
(sl)
|
2005-02-18 |
2016-07-29 |
Glaxosmithkline Biologicals S.A. |
Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso
|
|
JP2008530245A
(ja)
|
2005-02-18 |
2008-08-07 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド |
尿路病原性菌株由来の抗原
|
|
CA2626253A1
(en)
|
2005-10-18 |
2007-04-26 |
Novartis Vaccines And Diagnostics, Inc. |
Mucosal and systemic immunizations with alphavirus replicon particles
|
|
ES2514316T3
(es)
|
2005-11-22 |
2014-10-28 |
Novartis Vaccines And Diagnostics, Inc. |
Partículas similares a virus (VLPs) de Norovirus y Sapovirus
|
|
CA2633142A1
(en)
*
|
2005-12-22 |
2007-10-04 |
Novartis Vaccines And Diagnostics, S.R.L. |
Chlamydial antigens
|
|
AU2007281934B2
(en)
|
2006-01-18 |
2012-11-15 |
University Of Chicago |
Compositions and methods related to Staphylococcal bacterium proteins
|
|
ES2536426T3
(es)
|
2006-03-23 |
2015-05-25 |
Novartis Ag |
Compuestos de imidazoquinoxalina como inmunomoduladores
|
|
EP2586790A3
(en)
|
2006-08-16 |
2013-08-14 |
Novartis AG |
Immunogens from uropathogenic Escherichia coli
|
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
|
KR101621837B1
(ko)
|
2007-09-12 |
2016-05-17 |
노파르티스 아게 |
Gas57 돌연변이 항원 및 gas57 항체
|
|
CA2744739A1
(en)
|
2007-12-03 |
2009-06-11 |
President And Fellows Of Harvard College |
Chlamydia antigens
|
|
EP2537857B1
(en)
|
2007-12-21 |
2017-01-18 |
GlaxoSmithKline Biologicals SA |
Mutant forms of streptolysin O
|
|
WO2010032138A2
(en)
|
2008-09-18 |
2010-03-25 |
Novartis Ag |
Vaccine adjuvant combinations
|
|
CA2777837C
(en)
|
2008-10-27 |
2017-07-11 |
Novartis Ag |
Purification method
|
|
US8425922B2
(en)
|
2009-01-05 |
2013-04-23 |
EpitoGenesis, Inc. |
Adjuvant compositions and methods of use
|
|
CN103897045A
(zh)
|
2009-01-12 |
2014-07-02 |
诺华股份有限公司 |
抗革兰氏阳性细菌疫苗中的Cna_B结构域
|
|
US8568732B2
(en)
|
2009-03-06 |
2013-10-29 |
Novartis Ag |
Chlamydia antigens
|
|
ITMI20090946A1
(it)
|
2009-05-28 |
2010-11-29 |
Novartis Ag |
Espressione di proteine ricombinanti
|
|
JP5867952B2
(ja)
|
2009-06-10 |
2016-02-24 |
ノバルティス アーゲー |
ベンゾナフチリジン含有ワクチン
|
|
WO2011008400A2
(en)
|
2009-06-16 |
2011-01-20 |
Novartis Ag |
High-throughput complement-mediated antibody-dependent and opsonic bactericidal assays
|
|
WO2011026111A1
(en)
|
2009-08-31 |
2011-03-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Oral delivery of a vaccine to the large intestine to induce mucosal immunity
|
|
WO2011027222A2
(en)
|
2009-09-02 |
2011-03-10 |
Novartis Ag |
Immunogenic compositions including tlr activity modulators
|
|
JO3257B1
(ar)
|
2009-09-02 |
2018-09-16 |
Novartis Ag |
مركبات وتركيبات كمعدلات لفاعلية tlr
|
|
BR112012009014B8
(pt)
|
2009-09-30 |
2022-10-04 |
Novartis Ag |
Processo para preparar conjugado de polissacarídeo capsular de s. aureus tipo 5 ou tipo 8 e molécula de transporte crm197, conjugado e composição imunogênica
|
|
HUE034251T2
(en)
|
2009-10-30 |
2018-02-28 |
Glaxosmithkline Biologicals Sa |
Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
|
|
WO2011057148A1
(en)
|
2009-11-05 |
2011-05-12 |
Irm Llc |
Compounds and compositions as tlr-7 activity modulators
|
|
BR112012014624A8
(pt)
|
2009-12-15 |
2017-12-26 |
Novartis Ag |
suspensão homogênea de compostos de imunopotenciação e usos dos destes
|
|
EA031379B1
(ru)
|
2010-03-23 |
2018-12-28 |
Новартис Аг |
Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
|
|
EP2556377B1
(en)
|
2010-04-08 |
2017-07-12 |
University of Pittsburgh - Of the Commonwealth System of Higher Education |
B-cell antigen presenting cell assay
|
|
KR20130121699A
(ko)
|
2010-05-28 |
2013-11-06 |
테트리스 온라인, 인코포레이티드 |
상호작용 혼성 비동기 컴퓨터 게임 기반구조
|
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
|
AU2011295853A1
(en)
|
2010-09-01 |
2013-04-04 |
Irm Llc |
Adsorption of immunopotentiators to insoluble metal salts
|
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
|
ES2630029T3
(es)
|
2010-12-14 |
2017-08-17 |
Glaxosmithkline Biologicals Sa |
Análisis de citometría de flujo de materiales adsorbidos en sales metálicas
|
|
CA2860331A1
(en)
|
2010-12-24 |
2012-06-28 |
Novartis Ag |
Compounds
|
|
WO2012117377A1
(en)
|
2011-03-02 |
2012-09-07 |
Novartis Ag |
Combination vaccines with lower doses of antigen and/or adjuvant
|
|
US10561720B2
(en)
|
2011-06-24 |
2020-02-18 |
EpitoGenesis, Inc. |
Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
|
|
US9358284B2
(en)
|
2011-09-14 |
2016-06-07 |
Glaxosmithkline Biologicals Sa |
Methods for making saccharide-protein glycoconjugates
|
|
SI2822947T1
(sl)
|
2012-03-07 |
2016-10-28 |
Glaxosmithkline Biologicals S.A. |
Argininske soli TLR7 agonista
|
|
JP2015510872A
(ja)
|
2012-03-07 |
2015-04-13 |
ノバルティス アーゲー |
Streptococcuspneumoniae抗原の増強された製剤
|
|
MX372965B
(es)
|
2012-03-08 |
2020-04-01 |
Glaxosmithkline Biologicals Sa |
Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo.
|
|
RU2014151567A
(ru)
|
2012-05-22 |
2016-07-10 |
Новартис Аг |
Конъюгат менингококка серогруппы х
|
|
BR112015018014A2
(pt)
|
2013-02-01 |
2017-07-11 |
Glaxosmithkline Biologicals Sa |
liberação intradérmica de composições imunológicas compreendendo agonistas do receptor do tipo toll
|
|
JP7005504B2
(ja)
|
2016-02-22 |
2022-01-21 |
ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー |
生体分子の固定化方法
|
|
BE1024634B1
(fr)
|
2016-04-05 |
2018-05-14 |
Gsk Vaccines S.R.L. |
Compositions immunogenes
|
|
NL2019320B1
(en)
*
|
2017-03-02 |
2018-09-21 |
Biosparq B V |
Diagnostic method and system for diagnosis
|
|
JP7362667B2
(ja)
|
2018-02-12 |
2023-10-17 |
イニミューン・コーポレーション |
Toll様受容体リガンド
|
|
WO2020086408A1
(en)
|
2018-10-26 |
2020-04-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
A high-yield perfusion-based transient gene expression bioprocess
|
|
JP2023547677A
(ja)
|
2020-11-04 |
2023-11-13 |
エリゴ・バイオサイエンス |
キューティバクテリウム・アクネス組換えファージ、その産生方法及び使用
|
|
CN113637703B
(zh)
*
|
2021-08-06 |
2023-08-25 |
河北科技师范学院 |
一种布鲁氏菌L7/L12和GroES真核表达载体的构建方法及其应用
|